KALA BIO
NASDAQ: KALAArlington, US · Founded 2009 · Delaware corporation · 7 known investors
Find your way into KALA BIO
757 people in our graph share verified history with the KALA BIO team — schools, employers, funds. One of them is your warm intro.
Wesley Chanunlockedknows Justin Hanes · together at Massachusetts Institute of Technology (overlapped)
×7knows the team · via Massachusetts Institute of Technology
knows the team · via Johns Hopkins University
×2knows the team · via UCLA
knows the team · via University of Massachusetts Lowell
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
Founders & leadership
KALA BIO was founded in 2009 by Justin Hanes and Kevin Pojasek.
JH
KP
Kevin PojasekinCo-founder
DK
Darius KharabiinExecutive
TB
Todd BazemoreinInterim Chief Executive Officer2025–2025Todd Bazemore was a member of the executive leadership team at Dyax, a rare disease biotech company that was acquired by Shire for $6.5 billion in 2016. He has experience in healthcare executive roles focused on orphan and specialty pharmaceutical markets, with expertise in corporate strategy, capital raising, M&A, clinical and regulatory strategy, and product commercialization.
MI
Mark IwickiinBoard Chair2025–2026Mark Iwicki brings three decades of experience in pharmaceutical drug development and commercialization across multiple therapeutic areas. He has served as CEO of Inhibikase Therapeutics, Kala Bio, Civitas Pharmaceuticals, Blend Therapeutics, and Sunovion.
MR
Mary ReumuthinExecutive
KB
Kim BrazzellinExecutive
CM
Charles McDermottExecutive
HC
Hongming CheninExecutive
PC
Peter CourossiExecutive
DL
David LazarinChief Executive Officer, Chief Financial Officer, President, Chief Operating Officer and Chair of the BoardPresident at LQR House
RL
Robert LangerNamed on SEC filing
Investors · 7
Longitude CapitalMenlo Park · $10M – $30M
SR One Capital ManagementRedwood City
Ysios CapitalBarcelona · $5.4M – $21.6M
Atlas VenturereportedCambridge · $500K – $1Mvia Kevin Bitterman · board
Lux Capitalreported · 2 sourcesNew York · $100K – $100Mvia Robert Paull · board
RA CapitalreportedBoston
Third Rock Venturesreported · 3 sourcesBoston · $100K – $5Mvia Robert Tepper · board
Reported raises · per SEC filings
Form D private placements$148M disclosed across 9 of 13 rounds · 1900–2026
▶$1.8MraisedMar 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.8MraisedMar 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yonatan ColmanDirector
- Brendan PurdyDirector
- Chaim BergerDirector
- Avi MinkowitzExecutive Officer, Director
- Hillel PosenDirector
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Minimum investment
- $1.8M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2026 · 20 investors · BiotechnologyRule 506(b)
▶$2.3MraisedFeb 2026 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CHAIM BERGERDirector
- HILLEL POSENDirector
- AVI MINKOWITZExecutive Officer, Director
- DAVID LAZARDirector
- BRENDAN PURDYDirector
- YONATAN COLMANDirector
- Offering amount
- $4.2M
- Amount sold
- $2.3M
- Minimum investment
- $44.9K
- Sales commissions
- $39K
- Placement agents
- FM Global Markets Inc.
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.7MraisedDec 2024 · 6 investors · BiotechnologyRule 506(b)
▶$10.7MraisedDec 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Darius KharabiExecutive Officer
- Todd BazemoreExecutive Officer
- Gregory D. PerryDirector
- Marjan FaridDirector
- Andrew I. KovenDirector
- Howard B. RosenDirector
- Mark IwickiExecutive Officer, Director
- Mary ReumuthExecutive Officer
- C. Daniel MyersDirector
- Kim BrazzellExecutive Officer
- Offering amount
- $10.7M
- Amount sold
- $10.7M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.5MraisedJun 2024 · 5 investors · BiotechnologyRule 506(b)
▶$12.5MraisedJun 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark IwickiExecutive Officer, Director
- Kim BrazzellExecutive Officer
- Marjan FaridDirector
- Todd BazemoreExecutive Officer
- Mark S. BlumenkranzDirector
- Mary ReumuthExecutive Officer
- C. Daniel MyersDirector
- Darius KharabiExecutive Officer
- Gregory D. PerryDirector
- Andrew I. KovenDirector
- Howard B. RosenDirector
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.1MraisedNov 2021 · 26 investors · BiotechnologyRule 506(b)
▶$16.1MraisedNov 2021 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kim BrazzellExecutive Officer
- Gregory D. PerryDirector
- Mary ReumuthExecutive Officer
- Mark S. BlumenkranzDirector
- Andrew KovenDirector
- Darius KharabiExecutive Officer
- Howard B. RosenDirector
- Gregory GrunbergDirector
- Mark IwickiExecutive Officer, Director
- Hongming ChenExecutive Officer
- Robert PaullDirector
- Eric L. TrachtenbergExecutive Officer
- C. Daniel MyersDirector
- Todd BazemoreExecutive Officer
- Offering amount
- $36.5M
- Amount sold
- $16.1M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$67.9MraisedApr 2016 · 25 investors · BiotechnologyRule 506(b)
▶$67.9MraisedApr 2016 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin BittermanDirector
- Chen YuDirector
- Kim BrazzellExecutive Officer
- Charles McDermottExecutive Officer
- Robert TepperDirector
- Robert LangerDirector
- Robert PaullDirector
- Mark IwickiExecutive Officer, Director
- Greg GrunbergDirector
- Rajeev ShahDirector
- Howard B. RosenDirector
- Hongming ChenExecutive Officer
- Offering amount
- $67.9M
- Amount sold
- $67.9M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedAug 2015 · 1 investors · BiotechnologyRule 506(b)
▶$7MraisedAug 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles McDermottExecutive Officer
- Kevin BittermanDirector
- Robert TepperDirector
- Robert PaullDirector
- Kim BrazzellExecutive Officer
- Howard B. RosenDirector
- Karen WagnerDirector
- Mark IwickiExecutive Officer, Director
- Rajeev ShahDirector
- Robert LangerDirector
- Hongming ChenExecutive Officer
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.5MraisedApr 2014 · 16 investors · BiotechnologyRule 506(b)
▶$22.5MraisedApr 2014 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert TepperDirector
- Kevin BittermanDirector
- Robert PaullDirector
- Kim BrazzellExecutive Officer
- Howard B. RosenDirector
- Guillaume PfeferExecutive Officer, Director
- Bernard GillyDirector
- Robert LangerDirector
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$349.3Mvaluation at IPOJul 2017 · $15.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 2
by search overlap
Robinhood42 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits33 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with KALA BIO for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $255.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $180.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does KALA BIO do?
- A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
- Who founded KALA BIO?
- KALA BIO was founded by Justin Hanes, Kevin Pojasek in 2009.
- Who are KALA BIO's investors?
- KALA BIO's investors include Longitude Capital, SR One Capital Management, Ysios Capital, Atlas Venture, Lux Capital, RA Capital, Third Rock Ventures.
- How much funding has KALA BIO raised?
- KALA BIO has disclosed $148M raised across 9 of its 13 known rounds.
- Where is KALA BIO headquartered?
- KALA BIO is headquartered in Arlington, US.